Published in J Cell Biol on December 26, 2006
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev (2009) 4.29
Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res (2008) 3.45
Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res (2008) 2.96
In situ identification of bipotent stem cells in the mammary gland. Nature (2014) 2.71
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer (2013) 2.60
Beta1 integrin deletion from the basal compartment of the mammary epithelium affects stem cells. Nat Cell Biol (2008) 2.46
Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland. Breast Cancer Res (2012) 2.18
CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. Cancer Cell (2009) 2.17
Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer. Stem Cells (2008) 1.96
Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis. Cancer Cell (2010) 1.92
ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. Genes Dev (2013) 1.87
Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes Dev (2014) 1.86
Lgr5-expressing cells are sufficient and necessary for postnatal mammary gland organogenesis. Cell Rep (2013) 1.78
Cancer stem cells in breast: current opinion and future challenges. Pathobiology (2008) 1.77
Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci U S A (2008) 1.76
Minireview: hormones and mammary cell fate--what will I become when I grow up? Endocrinology (2008) 1.71
miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. Mol Cell Biol (2009) 1.70
Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics (2008) 1.70
Pygo2 expands mammary progenitor cells by facilitating histone H3 K4 methylation. J Cell Biol (2009) 1.65
Murine mammary epithelial stem cells: discovery, function, and current status. Cold Spring Harb Perspect Biol (2011) 1.63
Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res (2012) 1.55
LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Cancer Res (2011) 1.54
CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res (2010) 1.52
Integrated morphodynamic signalling of the mammary gland. Nat Rev Mol Cell Biol (2011) 1.50
Parity induces differentiation and reduces Wnt/Notch signaling ratio and proliferation potential of basal stem/progenitor cells isolated from mouse mammary epithelium. Breast Cancer Res (2013) 1.49
Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med (2007) 1.48
A putative role for microRNA-205 in mammary epithelial cell progenitors. J Cell Sci (2010) 1.47
Musashi1 modulates mammary progenitor cell expansion through proliferin-mediated activation of the Wnt and Notch pathways. Mol Cell Biol (2008) 1.47
Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res (2009) 1.42
s-SHIP promoter expression marks activated stem cells in developing mouse mammary tissue. Genes Dev (2010) 1.39
Mammary stem cells have myoepithelial cell properties. Nat Cell Biol (2014) 1.39
Breast cancer stem cells: tools and models to rely on. BMC Cancer (2009) 1.38
MMTV-Wnt1 and -DeltaN89beta-catenin induce canonical signaling in distinct progenitors and differentially activate Hedgehog signaling within mammary tumors. PLoS One (2009) 1.33
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. Nature (2015) 1.32
Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat (2012) 1.31
Re-evaluation of mammary stem cell biology based on in vivo transplantation. Breast Cancer Res (2008) 1.28
Pregnancy in the mature adult mouse does not alter the proportion of mammary epithelial stem/progenitor cells. Breast Cancer Res (2009) 1.25
Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. Proc Natl Acad Sci U S A (2012) 1.21
Telomerase-immortalized human mammary stem/progenitor cells with ability to self-renew and differentiate. Proc Natl Acad Sci U S A (2010) 1.15
Reproductive history and breast cancer risk. Breast Cancer (2012) 1.14
Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation. Mol Cancer (2014) 1.13
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Musashi1: a stem cell marker no longer in search of a function. Cell Cycle (2008) 1.09
The origin of breast tumor heterogeneity. Oncogene (2015) 1.09
CCAAT/enhancer binding protein beta regulates stem cell activity and specifies luminal cell fate in the mammary gland. Stem Cells (2010) 1.08
The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res (2010) 1.08
Notch3 marks clonogenic mammary luminal progenitor cells in vivo. J Cell Biol (2013) 1.06
Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage. Breast Cancer Res (2007) 1.06
Inhibition of peroxisome proliferator-activated receptor gamma increases estrogen receptor-dependent tumor specification. Cancer Res (2009) 1.03
NOTCH1 inhibition in vivo results in mammary tumor regression and reduced mammary tumorsphere-forming activity in vitro. Breast Cancer Res (2012) 1.02
Tumor-initiating function of nucleostemin-enriched mammary tumor cells. Cancer Res (2010) 1.02
The epigenetic landscape of mammary gland development and functional differentiation. J Mammary Gland Biol Neoplasia (2010) 1.02
Functional characterization of stem cell activity in the mouse mammary gland. Stem Cell Rev (2011) 0.98
Transcriptome analysis of embryonic mammary cells reveals insights into mammary lineage establishment. Breast Cancer Res (2011) 0.97
Aldehyde dehydrogenase and estrogen receptor define a hierarchy of cellular differentiation in the normal human mammary epithelium. Breast Cancer Res (2014) 0.97
New insights into lineage restriction of mammary gland epithelium using parity-identified mammary epithelial cells. Breast Cancer Res (2014) 0.96
Wnt5a as an effector of TGFβ in mammary development and cancer. J Mammary Gland Biol Neoplasia (2011) 0.96
Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol (2011) 0.93
A novel mouse model for non-invasive single marker tracking of mammary stem cells in vivo reveals stem cell dynamics throughout pregnancy. PLoS One (2009) 0.93
Jekyll or Hyde: does Matrigel provide a more or less physiological environment in mammary repopulating assays? Breast Cancer Res (2011) 0.93
STAT3 mediates resistance of CD44(+)CD24(-/low) breast cancer stem cells to tamoxifen in vitro. J Biomed Res (2012) 0.91
Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers. Breast Cancer Res Treat (2013) 0.91
Stem and progenitor cell division kinetics during postnatal mouse mammary gland development. Nat Commun (2015) 0.90
Hormone-sensing cells require Wip1 for paracrine stimulation in normal and premalignant mammary epithelium. Breast Cancer Res (2013) 0.90
Pregnancy-induced noncoding RNA (PINC) associates with polycomb repressive complex 2 and regulates mammary epithelial differentiation. PLoS Genet (2012) 0.90
ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells. PLoS One (2014) 0.89
Regulator of G-protein signalling 2 mRNA is differentially expressed in mammary epithelial subpopulations and over-expressed in the majority of breast cancers. Breast Cancer Res (2007) 0.89
Luminal progenitors restrict their lineage potential during mammary gland development. PLoS Biol (2015) 0.89
Response of estrogen receptor-positive breast cancer tumorspheres to antiestrogen treatments. PLoS One (2011) 0.89
Stem cell marker prominin-1 regulates branching morphogenesis, but not regenerative capacity, in the mammary gland. Dev Dyn (2011) 0.89
Ovarian hormones are not required for PRL-induced mammary tumorigenesis, but estrogen enhances neoplastic processes. J Endocrinol (2009) 0.88
Form and Function: how Estrogen and Progesterone Regulate the Mammary Epithelial Hierarchy. J Mammary Gland Biol Neoplasia (2015) 0.88
The future of mammary stem cell biology: the power of in vivo transplants. Breast Cancer Res (2008) 0.88
RANK Signaling Amplifies WNT-Responsive Mammary Progenitors through R-SPONDIN1. Stem Cell Reports (2015) 0.88
Stem cells and the developing mammary gland. J Mammary Gland Biol Neoplasia (2013) 0.87
A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells. J Steroid Biochem Mol Biol (2011) 0.87
It's all in the details: methods in breast development and cancer. Breast Cancer Res (2009) 0.87
Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and Generates Rare Breast Cancer Subtypes. Genes Cancer (2012) 0.86
Tamoxifen prevents premalignant changes of breast, but not ovarian, cancer in rats at high risk for both diseases. Cancer Prev Res (Phila) (2008) 0.85
Stem cell antigen-1 (sca-1) regulates mammary tumor development and cell migration. PLoS One (2011) 0.85
The WNT-controlled transcriptional regulator LBH is required for mammary stem cell expansion and maintenance of the basal lineage. Development (2015) 0.84
Wnt signaling can substitute for estrogen to induce division of ERalpha-positive cells in a mouse mammary tumor model. Cancer Lett (2009) 0.84
The mammary cellular hierarchy and breast cancer. Cell Mol Life Sci (2014) 0.84
Separation by cell size enriches for mammary stem cell repopulation activity. Stem Cells Transl Med (2013) 0.84
Tumorigenic WAP-T mouse mammary carcinoma cells: a model for a self-reproducing homeostatic cancer cell system. PLoS One (2010) 0.83
The bed and the bugs: interactions between the tumor microenvironment and cancer stem cells. Semin Cancer Biol (2012) 0.83
Aberrant Proliferation of Differentiating Alveolar Cells Induces Hyperplasia in Resting Mammary Glands of SV40-TAg Transgenic Mice. Front Oncol (2014) 0.83
Integration of microRNA signatures of distinct mammary epithelial cell types with their gene expression and epigenetic portraits. Breast Cancer Res (2015) 0.82
Cell hierarchy and lineage commitment in the bovine mammary gland. PLoS One (2012) 0.82
ERrrr…Where are the Progenitors? Hormone Receptors and Mammary Cell Heterogeneity. J Mammary Gland Biol Neoplasia (2015) 0.79
Prospective isolation and characterization of committed and multipotent progenitors from immortalized mouse mammary epithelial cells with morphogenic potential. Breast Cancer Res (2011) 0.79
A pooled shRNA screen for regulators of primary mammary stem and progenitor cells identifies roles for Asap1 and Prox1. BMC Cancer (2015) 0.79
Mouse mammary stem cells express prognostic markers for triple-negative breast cancer. Breast Cancer Res (2015) 0.78
A Long-Lived Luminal Subpopulation Enriched with Alveolar Progenitors Serves as Cellular Origin of Heterogeneous Mammary Tumors. Stem Cell Reports (2015) 0.77
Comparison of the transcriptomes of long-term label retaining-cells and control cells microdissected from mammary epithelium: an initial study to characterize potential stem/progenitor cells. Front Oncol (2013) 0.77
Long-term cultures of stem/progenitor cells from lobular and ductal breast carcinomas under non-adherent conditions. Cytotechnology (2010) 0.77
Paracrine Met signaling triggers epithelial-mesenchymal transition in mammary luminal progenitors, affecting their fate. Elife (2015) 0.76
Single-cell lineage tracing in the mammary gland reveals stochastic clonal dispersion of stem/progenitor cell progeny. Nat Commun (2016) 0.76
Role of dietary bioactive natural products in estrogen receptor-positive breast cancer. Semin Cancer Biol (2016) 0.76
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Generation of a functional mammary gland from a single stem cell. Nature (2006) 18.30
Purification and unique properties of mammary epithelial stem cells. Nature (2006) 15.98
Estrogen carcinogenesis in breast cancer. N Engl J Med (2006) 8.17
Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fat pads of female C3H mice. Cancer Res (1959) 7.35
Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev Biol (2002) 5.74
CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res (2005) 4.79
Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res (1997) 4.22
Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci U S A (2006) 3.32
A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev Biol (2005) 3.19
Label-retaining epithelial cells in mouse mammary gland divide asymmetrically and retain their template DNA strands. Development (2005) 3.14
Experimental mammary epithelial morphogenesis in an in vivo model: evidence for distinct cellular progenitors of the ductal and lobular phenotype. Breast Cancer Res Treat (1996) 3.00
Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res (2004) 2.82
Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis. Breast Cancer Res (2005) 2.46
The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med (2005) 2.01
Estrogen receptor-negative epithelial cells in mouse mammary gland development and growth. Differentiation (1998) 1.89
Clonal characterization of mouse mammary luminal epithelial and myoepithelial cells separated by fluorescence-activated cell sorting. In Vitro Cell Dev Biol Anim (1998) 1.74
Estrogen receptors ER alpha and ER beta in proliferation in the rodent mammary gland. Proc Natl Acad Sci U S A (2004) 1.66
The mammary gland "side population": a putative stem/progenitor cell marker? J Mammary Gland Biol Neoplasia (2005) 1.57
Selective coactivation of estrogen-dependent transcription by CITED1 CBP/p300-binding protein. Genes Dev (2001) 1.53
Cloning and characterization of a cDNA encoding a highly conserved, putative calcium binding protein, identified by an anti-prolactin receptor antiserum. J Biol Chem (1988) 1.14
Expression of CD44 isoforms in normal salivary gland tissue: an immunohistochemical and ultrastructural study. Histochem Cell Biol (2000) 1.06
Murine progesterone receptor expression in proliferating mammary epithelial cells during normal pubertal development and adult estrous cycle. Association with eralpha and erbeta status. J Histochem Cytochem (1999) 1.05
An improved definition of mouse mammary epithelial side population cells. Cytotherapy (2005) 0.90
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Translating cancer research into targeted therapeutics. Nature (2010) 7.33
Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol (2010) 6.88
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res (2006) 6.28
CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature (2003) 6.00
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
The DNA damage response and cancer therapy. Nature (2012) 5.25
CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res (2005) 4.79
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 4.68
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell (2010) 4.66
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J (2005) 4.31
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res (2010) 3.89
Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res (2011) 3.88
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
A HaemAtlas: characterizing gene expression in differentiated human blood cells. Blood (2009) 3.63
Stem cells and breast cancer: A field in transit. Nat Rev Cancer (2003) 3.47
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. J Natl Cancer Inst (2011) 3.05
The mannose receptor family. Biochim Biophys Acta (2002) 3.02
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J (2008) 2.95
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature (2012) 2.66
Functional and molecular characterisation of mammary side population cells. Breast Cancer Res (2002) 2.63
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov (2012) 2.53
Functional viability profiles of breast cancer. Cancer Discov (2011) 2.44
Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov (2007) 2.43
Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A (2007) 2.41
Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol (2008) 2.40
Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation (2005) 2.39
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood (2012) 2.38
A distinct spectrum of copy number aberrations in pediatric high-grade gliomas. Clin Cancer Res (2010) 2.37
The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell (2008) 2.27
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. Am J Hum Genet (2013) 2.24
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J Pathol (2009) 2.17
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res (2006) 2.15
Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer (2008) 2.11
Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. Am J Physiol Endocrinol Metab (2005) 2.04
Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim Biophys Acta (2004) 2.04
Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. Breast Cancer Res (2006) 2.03
Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol (2011) 1.99
The sympathetic nervous system in hypertension: assessment by blood pressure variability and ganglionic blockade. J Hypertens (2003) 1.98
The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med (2002) 1.97
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2010) 1.96
Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett (2005) 1.96
Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med (2013) 1.94
LKB1 is essential for the proliferation of T-cell progenitors and mature peripheral T cells. Eur J Immunol (2010) 1.94
A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nat Cell Biol (2002) 1.94
Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov (2013) 1.93
An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat (2009) 1.93
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res (2011) 1.90
A divergent canonical WNT-signaling pathway regulates microtubule dynamics: dishevelled signals locally to stabilize microtubules. J Cell Biol (2004) 1.90
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell (2008) 1.90
Postural pseudoanemia: posture-dependent change in hematocrit. Mayo Clin Proc (2005) 1.89
MAP kinase phosphatases. Genome Biol (2002) 1.88
Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol (2011) 1.86
A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein. EMBO J (2003) 1.82
Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci (2011) 1.82
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res (2012) 1.81
The relationship between obesity and exposure to light at night: cross-sectional analyses of over 100,000 women in the Breakthrough Generations Study. Am J Epidemiol (2014) 1.80
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma. Sci Transl Med (2011) 1.79
Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas. J Pathol (2010) 1.79
BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther (2005) 1.76
Water ingestion as prophylaxis against syncope. Circulation (2003) 1.76
Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue. BMC Cell Biol (2008) 1.75
Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol (2005) 1.75
Women have lower tonic autonomic support of arterial blood pressure and less effective baroreflex buffering than men. Circulation (2005) 1.75
Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet (2007) 1.74
Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Hum Mol Genet (2004) 1.73
DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev (2008) 1.73
Pregnancy and the risk of breast cancer. Endocr Relat Cancer (2007) 1.72
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) (2008) 1.70
Transcriptome analysis of mammary epithelial subpopulations identifies novel determinants of lineage commitment and cell fate. BMC Genomics (2008) 1.70
Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension (2010) 1.69
Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res (2009) 1.68
Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J (2009) 1.68
Neurovascular dissociation with paradoxical forearm vasodilation during systemic tyramine administration. Circulation (2003) 1.68
Renal impairment of pure autonomic failure. Hypertension (2009) 1.67
Four faces of baroreflex failure: hypertensive crisis, volatile hypertension, orthostatic tachycardia, and malignant vagotonia. Circulation (2002) 1.67
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle (2011) 1.65
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med (2010) 1.64
Familial concordance for age at natural menopause: results from the Breakthrough Generations Study. Menopause (2011) 1.63
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov (2012) 1.62
Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nat Rev Clin Oncol (2010) 1.62
Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res (2007) 1.61
Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation (2009) 1.61
Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome. Heart Rhythm (2012) 1.60
Water drinking as a treatment for orthostatic syndromes. Am J Med (2002) 1.60